(Información remitida por la empresa firmante)
[3] Multiple endpoints: CDR-SB, a numeric scale used to quantify the severity of symptoms of dementia; ADAS-Cog14, common cognitive assessment instrument used in AD clinical trials all over the world; and ADCS MCI-ADL, a scale to assess the parties’ activities of daily living.[4] One of the AD pathological features is the accumulation of clusters (plaques) of amyloid beta (Aß) in the brain. The formation of these plaques is the result of a continuous process by which individual Aß proteins join together, latching onto each other, one at a time, like adding links to a chain. In the early part of this process these small chains of Aß are soluble and are toxic to the nerves within the brain. The most toxic of the soluble chains is called a protofibril. Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aß, having a primary role in the cognitive decline associated with this progressive, debilitating condition. Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aß plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.
The following files are available for download:
https://mb.cision.com/Main/9978/3862461/2386751.pdf New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD
View original content:https://www.prnewswire.co.uk/news-releases/new-data-from-leqembi-lecanemab-irmb-phase-3-clarity-ad-study-and-subcutaneous-formulation-presented-at-ctad-301968090.html